Generali Asset Management SPA SGR Makes New $952,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Generali Asset Management SPA SGR acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 7,733 shares of the specialty pharmaceutical company’s stock, valued at approximately $952,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $25,000. Jones Financial Companies Lllp raised its holdings in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares during the period. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the period. Lindbrook Capital LLC lifted its position in Jazz Pharmaceuticals by 82.6% in the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 176 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its stake in Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ:JAZZ opened at $140.57 on Friday. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market capitalization of $8.54 billion, a P/E ratio of 19.80, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a 50-day simple moving average of $131.07 and a 200 day simple moving average of $121.46.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research reports. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Royal Bank of Canada cut their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Finally, Barclays reaffirmed an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,022,825 over the last 90 days. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.